Profile of bictegravir/emtricitabine/tenofovir alafenamide fixed dose combination and its potential in the treatment of HIV-1 infection: evidence to date

Lucas Hill,1 Shawn R Smith,1 Maile Young Karris2 1University of California San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, San Diego, CA, USA; 2Department of Medicine, University of California San Diego, San Diego, CA, USA Abstract: Modern pharmacologic management of people living w...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hill L, Smith SR, Karris MY
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	Biktarvy HIV care review Integrase strand transfer inhibitor Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/3c4c1b585123436693f901fe0c625251
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3c4c1b585123436693f901fe0c625251
record_format	dspace
spelling	oai:doaj.org-article:3c4c1b585123436693f901fe0c6252512021-12-02T05:14:13ZProfile of bictegravir/emtricitabine/tenofovir alafenamide fixed dose combination and its potential in the treatment of HIV-1 infection: evidence to date1179-1373https://doaj.org/article/3c4c1b585123436693f901fe0c6252512018-10-01T00:00:00Zhttps://www.dovepress.com/profile-of-bictegraviremtricitabinetenofovir-alafenamide-fixed-dose-co-peer-reviewed-article-HIVhttps://doaj.org/toc/1179-1373Lucas Hill,1 Shawn R Smith,1 Maile Young Karris2 1University of California San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, San Diego, CA, USA; 2Department of Medicine, University of California San Diego, San Diego, CA, USA Abstract: Modern pharmacologic management of people living with HIV involves the use of fixed dose combinations of antiretrovirals that are simple to take, well tolerated, and highly effective. Specific recent pharmacologic advancements include 1) the second-generation integrase strand transfer inhibitors (dolutegravir and bictegravir) that consistently show less side effects, high tolerability, minimal drug interactions, and rapid rates of HIV viral load decline and 2) tenofovir alafenamide, a prodrug of tenofovir that concentrates in lymphoid tissue and minimizes off target effects. Bictegravir/emtricitabine/tenofovir alafenamide or B/F/TAF is a recently approved fixed dose combination that incorporates these new advancements in the management of HIV. This review focuses on the data supporting the use of B/F/TAF, reviews clinically relevant findings, and highlights the unanswered questions that may limit its clinical utility. Keywords: Biktarvy, HIV care, review, integrase strand transfer inhibitorHill LSmith SRKarris MYDove Medical PressarticleBiktarvyHIV carereviewIntegrase strand transfer inhibitorImmunologic diseases. AllergyRC581-607ENHIV/AIDS: Research and Palliative Care, Vol Volume 10, Pp 203-213 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Biktarvy HIV care review Integrase strand transfer inhibitor Immunologic diseases. Allergy RC581-607
spellingShingle	Biktarvy HIV care review Integrase strand transfer inhibitor Immunologic diseases. Allergy RC581-607 Hill L Smith SR Karris MY Profile of bictegravir/emtricitabine/tenofovir alafenamide fixed dose combination and its potential in the treatment of HIV-1 infection: evidence to date
description	Lucas Hill,1 Shawn R Smith,1 Maile Young Karris2 1University of California San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, San Diego, CA, USA; 2Department of Medicine, University of California San Diego, San Diego, CA, USA Abstract: Modern pharmacologic management of people living with HIV involves the use of fixed dose combinations of antiretrovirals that are simple to take, well tolerated, and highly effective. Specific recent pharmacologic advancements include 1) the second-generation integrase strand transfer inhibitors (dolutegravir and bictegravir) that consistently show less side effects, high tolerability, minimal drug interactions, and rapid rates of HIV viral load decline and 2) tenofovir alafenamide, a prodrug of tenofovir that concentrates in lymphoid tissue and minimizes off target effects. Bictegravir/emtricitabine/tenofovir alafenamide or B/F/TAF is a recently approved fixed dose combination that incorporates these new advancements in the management of HIV. This review focuses on the data supporting the use of B/F/TAF, reviews clinically relevant findings, and highlights the unanswered questions that may limit its clinical utility. Keywords: Biktarvy, HIV care, review, integrase strand transfer inhibitor
format	article
author	Hill L Smith SR Karris MY
author_facet	Hill L Smith SR Karris MY
author_sort	Hill L
title	Profile of bictegravir/emtricitabine/tenofovir alafenamide fixed dose combination and its potential in the treatment of HIV-1 infection: evidence to date
title_short	Profile of bictegravir/emtricitabine/tenofovir alafenamide fixed dose combination and its potential in the treatment of HIV-1 infection: evidence to date
title_full	Profile of bictegravir/emtricitabine/tenofovir alafenamide fixed dose combination and its potential in the treatment of HIV-1 infection: evidence to date
title_fullStr	Profile of bictegravir/emtricitabine/tenofovir alafenamide fixed dose combination and its potential in the treatment of HIV-1 infection: evidence to date
title_full_unstemmed	Profile of bictegravir/emtricitabine/tenofovir alafenamide fixed dose combination and its potential in the treatment of HIV-1 infection: evidence to date
title_sort	profile of bictegravir/emtricitabine/tenofovir alafenamide fixed dose combination and its potential in the treatment of hiv-1 infection: evidence to date
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/3c4c1b585123436693f901fe0c625251
work_keys_str_mv	AT hilll profileofbictegraviremtricitabinetenofoviralafenamidefixeddosecombinationanditspotentialinthetreatmentofhiv1infectionevidencetodate AT smithsr profileofbictegraviremtricitabinetenofoviralafenamidefixeddosecombinationanditspotentialinthetreatmentofhiv1infectionevidencetodate AT karrismy profileofbictegraviremtricitabinetenofoviralafenamidefixeddosecombinationanditspotentialinthetreatmentofhiv1infectionevidencetodate
_version_	1718400463904178176

Profile of bictegravir/emtricitabine/tenofovir alafenamide fixed dose combination and its potential in the treatment of HIV-1 infection: evidence to date

Ejemplares similares